Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?

Company Overview - Keros Therapeutics, Inc. (KROS) shares increased by 5.1% to close at $11.41, following a significant trading volume compared to normal sessions, despite a 36.6% loss over the past four weeks [1] Recent Developments - The global development and commercialization license agreement with Takeda for elritercept became effective on January 16, 2025, with Takeda set to make an upfront payment of $200 million to Keros Therapeutics, potentially contributing to the recent share price rally [2] Financial Expectations - Keros Therapeutics is expected to report a quarterly loss of $0.93 per share, reflecting a year-over-year increase of 30.6%, while revenues are projected to be $105.25 million, a substantial increase of 75078.6% from the same quarter last year [3] - The consensus EPS estimate for the quarter has been revised 2.7% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Keros Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Revolution Medicines, Inc. (RVMD), experienced a 0.3% decline to $40.16, with a return of -8.3% over the past month [4]